Home › News › Quality / GMP

Alembic Pharmaceuticals Receives USFDA Approval for Binimetinib Tablets

Alembic Pharmaceuticals Receives USFDA Approval for Binimetinib Tablets

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for binimetinib tablets in 15 mg and 45 mg strengths. The approved generic product is therapeutically equivalent to Mektovi tablets, the reference listed drug marketed by Array BioPharma.

Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for treating patients with unresectable or metastatic melanoma carrying BRAF V600E or V600K mutations. The combination is also indicated for adults with metastatic Non-Small Cell Lung Cancer (NSCLC) carrying a BRAF V600E mutation.

Alembic was among the first applicants to submit a substantially complete ANDA with a Paragraph IV certification for the 15 mg strength and was the sole first applicant for the 45 mg strength. Following the approval, the company is eligible for 180 days of generic drug exclusivity for both strengths.

According to IQVIA data, the US market for binimetinib tablets was estimated at USD 282 million for the 12 months ending September 2026.

More news about: quality / gmp | Published by News Bureau | November - 17 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members